Abstract: Objective:To investigate the clinical effects between deanxit and doxepin in the treatment of post-stroke depression,and its effects on the neurotransmitter level.Methods:Eighty patients with post-stroke depression were randomly divided into the deanxit group and doxepin group(40 cases each group).The deanxit group and doxepin group were treated with the deanxit and doxepin for 8 weeks,respectively.The clinical effects between two groups were evaluated using the Hamilton Depression Rating Scale(HAMD),US National Institutes of Health Stroke Scale(NIHSS) and Barthel index(BI).The levels of 5-HT and DA in two groups were detected by fluorescence spectrophotometer method,and the level of NE in two groups were detected by high performance liquid chromatography(HPLC).Results:The total effective rate in deanxit group was significantly better than that in doxepin group(P<0.01).Compared before treatment,the scores of HAMD and NIHSS,and Barthel index in two groups significantly decreased and increased after treatment,respectively(P<0.01),After 2,4 and 8 weeks of treatment,the HAMD scores in deanxit group were lower than those in doxepin group(P<0.05 to P<0.01),and the Barthel index in deanxit group was higher than that in doxepin group(P<0.05 to P<0.01).The NIHSS score in deanxit group after 8 weeks of treatment was significantly lower than that in doxepin group(P<0.01).Compared before treatment,the levels of 5-HT,DA and NE in two groups significantly increased after treatment(P<0.01),and the incrasing degree of 5-HT,DA and NE levels in deanxit group were significantly higher than those in doxepin group after treatment(P<0.01).The difference of the incidence rate of adverse reaction between two groups was not statistically signficant(P>0.05).Conclusions:The treatment of post-stroke depression with deanxit is good effect and safe,which can effectively increase the neurotransmitter level,promote the nerve function recovery,improve the daily life ability of patients,and is worthy of clinical use.